Announcements Trials
Browse Landscape

Phase

Phase 2 53Phase 1 31Phase 3 20Phase NA 17Phase 1/2 16Phase EARLY_PHASE1 5Phase 4 3Phase 2/3 3

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 86Thoracic 45Other hematologic neoplasm 38Genitourinary 37Lymphoid 33Head & Neck 29Gynecologic 29Breast 23CNS 17Dermatologic 15Sarcoma 11Plasma cell 10Endocrine 9Tumor-Agnostic 8Myeloid 7Other solid neoplasm 4Other 3NET 3Classical hematology 3Other neoplasm 1

Conditions

Neuroendocrine Tumors 2Neoplasm Metastasis 1Gastroenteropancreatic Neuroendocrine Tumors 1Adenoma, Islet Cell 1

Interventions

Everolimus 2Sirolimus 1Injections 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × NET × 1 year × Clear all
NCT01744249 2026-04-28

Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas

Grupo Espanol de Tumores Neuroendocrinos

Phase 2/3 Completed
256 enrolled 25 charts
EndocrineNET

Neuroendocrine Tumors

NCT07165886 2026-04-24

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2/3 Recruiting
298 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

NCT06943755 2026-04-17

STELLAR-311

Exelixis

Phase 2/3 Recruiting
440 enrolled
EndocrineNET

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡